Quoin Pharmaceuticals Ltd.
- Tickers
- QNRX
- Headquarters
- Not recorded
- SEC CIK
- 0001671502
- Website
- Not recorded
Closing prices
Latest close, 4.15
| Date | Close |
|---|---|
| 10.33 | |
| 9.86 | |
| 9.65 | |
| 8.57 | |
| 9.01 | |
| 8.14 | |
| 11.51 | |
| 12.09 | |
| 13.42 | |
| 15.03 | |
| 16.21 | |
| 19.24 | |
| 18.18 | |
| 18.42 | |
| 18.30 | |
| 19.59 | |
| 22.30 | |
| 20.72 | |
| 21.75 | |
| 19.36 | |
| 19.17 | |
| 17.83 | |
| 18.91 | |
| 12.09 | |
| 15.05 | |
| 12.41 | |
| 11.92 | |
| 11.36 | |
| 10.30 | |
| 10.27 | |
| 11.72 | |
| 14.60 | |
| 13.82 | |
| 14.20 | |
| 13.75 | |
| 13.35 | |
| 13.90 | |
| 13.99 | |
| 14.45 | |
| 13.50 | |
| 14.43 | |
| 14.08 | |
| 14.05 | |
| 13.93 | |
| 13.75 | |
| 13.15 | |
| 12.21 | |
| 11.72 | |
| 10.91 | |
| 11.27 | |
| 10.66 | |
| 10.27 | |
| 10.45 | |
| 9.97 | |
| 9.66 | |
| 9.60 | |
| 9.60 | |
| 9.44 | |
| 9.10 | |
| 8.30 | |
| 7.22 | |
| 8.00 | |
| 7.53 | |
| 7.37 | |
| 7.82 | |
| 7.14 | |
| 7.13 | |
| 7.50 | |
| 8.02 | |
| 8.27 | |
| 8.40 | |
| 8.96 | |
| 9.47 | |
| 9.38 | |
| 8.61 | |
| 8.19 | |
| 8.74 | |
| 8.50 | |
| 8.51 | |
| 8.37 | |
| 8.52 | |
| 8.74 | |
| 8.50 | |
| 8.57 | |
| 8.67 | |
| 8.43 | |
| 8.59 | |
| 8.49 | |
| 8.09 | |
| 8.06 | |
| 8.20 | |
| 8.14 | |
| 7.84 | |
| 8.26 | |
| 7.94 | |
| 8.16 | |
| 8.00 | |
| 9.27 | |
| 7.57 | |
| 6.41 | |
| 6.28 | |
| 6.60 | |
| 6.06 | |
| 7.02 | |
| 6.44 | |
| 6.32 | |
| 5.99 | |
| 5.74 | |
| 5.90 | |
| 5.92 | |
| 6.30 | |
| 6.49 | |
| 6.58 | |
| 6.46 | |
| 6.25 | |
| 6.04 | |
| 5.74 | |
| 5.73 | |
| 5.70 | |
| 5.46 | |
| 5.45 | |
| 5.93 | |
| 6.48 | |
| 6.21 | |
| 6.36 | |
| 6.31 | |
| 6.43 | |
| 6.37 | |
| 5.93 | |
| 6.28 | |
| 6.07 | |
| 5.91 | |
| 5.81 | |
| 5.79 | |
| 5.53 | |
| 5.17 | |
| 4.94 | |
| 4.85 | |
| 4.77 | |
| 4.84 | |
| 5.00 | |
| 4.94 | |
| 5.06 | |
| 4.77 | |
| 4.56 | |
| 4.43 | |
| 4.29 | |
| 4.49 | |
| 4.57 | |
| 4.95 | |
| 5.06 | |
| 4.70 | |
| 4.20 | |
| 4.65 | |
| 4.46 | |
| 4.62 | |
| 4.65 | |
| 4.41 | |
| 3.25 | |
| 3.83 | |
| 4.20 | |
| 4.45 | |
| 4.55 | |
| 4.84 | |
| 4.71 | |
| 4.58 | |
| 4.60 | |
| 4.80 | |
| 4.72 | |
| 4.67 | |
| 4.45 | |
| 4.23 | |
| 4.35 | |
| 4.21 | |
| 4.16 | |
| 4.24 | |
| 4.21 | |
| 4.26 | |
| 4.38 | |
| 4.37 | |
| 4.28 | |
| 4.29 | |
| 4.20 | |
| 4.28 | |
| 4.40 | |
| 4.45 | |
| 4.45 | |
| 4.35 | |
| 4.37 | |
| 4.57 | |
| 4.79 | |
| 5.36 | |
| 5.35 | |
| 5.89 | |
| 6.05 | |
| 5.09 | |
| 5.19 | |
| 4.97 | |
| 4.72 | |
| 4.99 | |
| 5.57 | |
| 5.42 | |
| 5.07 | |
| 5.18 | |
| 5.16 | |
| 6.12 | |
| 6.22 | |
| 6.51 | |
| 6.74 | |
| 7.87 | |
| 7.26 | |
| 7.15 | |
| 6.97 | |
| 6.90 | |
| 6.79 | |
| 6.88 | |
| 6.80 | |
| 6.90 | |
| 7.01 | |
| 7.06 | |
| 6.90 | |
| 7.01 | |
| 6.75 | |
| 6.38 | |
| 6.43 | |
| 5.26 | |
| 4.88 | |
| 4.56 | |
| 4.72 | |
| 4.47 | |
| 4.56 | |
| 4.72 | |
| 4.70 | |
| 4.55 | |
| 4.50 | |
| 4.36 | |
| 4.15 | |
| 4.10 | |
| 4.03 | |
| 3.90 | |
| 3.98 | |
| 4.04 | |
| 3.99 | |
| 4.01 | |
| 4.02 | |
| 4.01 | |
| 4.05 | |
| 4.11 | |
| 4.15 |
Drugs
| Drug | Indications | Phase | Next catalyst | CT-VCA | Trials |
|---|---|---|---|---|---|
| QRX003 | Netherton Syndrome | Phase 2/3 | None scheduled | 3 |
FDA-approved applications
No Drugs@FDA application has a sponsor name that matches this company.
Data provided by the U.S. Food and Drug Administration (Drugs@FDA). Sponsors are matched to companies by name; subsidiaries do not link.
Catalysts
No catalysts yet. Editors add each date together with its source.
Deals
No approved deals involve this company yet.
Reported fundamentals (SEC XBRL)
| Metric | Reported value | Period | Filing |
|---|---|---|---|
| Revenue | 0 USD | 1 Jan 2021 to 31 Dec 2021 FY2021 | 20-F for Revenue on sec.gov (opens in a new tab)Filed |
| Net income (loss) | −5,371,042 USD | 1 Apr 2026 to 30 Jun 2026 FY2026 Q2 | 10-Q for Net income (loss) on sec.gov (opens in a new tab)Filed |
| Research and development expense | 3,627,168 USD | 1 Apr 2026 to 30 Jun 2026 FY2026 Q2 | 10-Q for Research and development expense on sec.gov (opens in a new tab)Filed |
| Operating expenses | Not reported in XBRL filings since 2015 | ||
| Cash and cash equivalents | 3,845,606 USD | At 30 Jun 2026 FY2026 Q2 | 10-Q for Cash and cash equivalents on sec.gov (opens in a new tab)Filed |
| Short-term investments and marketable securities | 6,954,476 USD | At 30 Jun 2026 FY2026 Q2 | 10-Q for Short-term investments and marketable securities on sec.gov (opens in a new tab)Filed |
| Total liabilities | 8,036,891 USD | At 30 Jun 2026 FY2026 Q2 | 10-Q for Total liabilities on sec.gov (opens in a new tab)Filed |
| Stockholders' equity | 3,932,671 USD | At 30 Jun 2026 FY2026 Q2 | 10-Q for Stockholders' equity on sec.gov (opens in a new tab)Filed |
| Common shares outstanding (cover page) | 70,294,615 shares | At 12 Aug 2026 FY2026 Q2 | 10-Q for Common shares outstanding (cover page) on sec.gov (opens in a new tab)Filed |
History
| Period | Reported value | Filing |
|---|---|---|
| 1 Jan 2021 to 31 Dec 2021 FY2021 | 0 USD | 20-F filed 14 Apr 2022 on sec.gov (opens in a new tab)Filed |
| 1 Jan 2020 to 31 Dec 2020 FY2021 | 0 USD | 20-F filed 14 Apr 2022 on sec.gov (opens in a new tab)Filed |
| 1 Jan 2019 to 31 Dec 2019 FY2021 | 0 USD | 20-F filed 14 Apr 2022 on sec.gov (opens in a new tab)Filed |
Values as reported in the company's XBRL filings to the SEC, one per calendar period (SEC frames); not adjusted, not audited by HealthTrade, and not investment advice.
Source: SEC XBRL company facts (opens in a new tab) · Licence: public-domain · as of 2026-10-25 · read
SEC filings
Source: SEC EDGAR. Each row links to the filing on sec.gov.
Related news
No recent headlines mention this company.
Insider transactions
All rows for Quoin Pharmaceuticals Ltd. on Insider TradesLast 90 days of Form 4 filings, from 3 Aug 2026 (US Eastern dates).
- Buys code P
- 4 transactions, 57,370 shares, $279,965.60
- Sells code S
- None in this period
- Other all other codes
- 2 transactions: grants, exercises, tax withholding, gifts and similar
Last transaction:
Insider filings are public records and are not a recommendation. Source: SEC EDGAR.
Sources
- Editor source (opens in a new tab) Licence: editorial. Entered by an editor, not fetched automatically
- SEC EDGAR submissions (opens in a new tab) Licence: public-domain. Fetched
Nothing on this page is investment advice.